These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34813050)

  • 21. Atogepant (Qulipta®) for migraine prevention.
    Hay DL; Walker CS; Harris PWR
    Trends Pharmacol Sci; 2022 Aug; 43(8):701-702. PubMed ID: 35469689
    [No Abstract]   [Full Text] [Related]  

  • 22. Erenumab: First Global Approval.
    Markham A
    Drugs; 2018 Jul; 78(11):1157-1161. PubMed ID: 29968151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis.
    Hou M; Luo X; He S; Yang X; Zhang Q; Jin M; Zhang P; Li Y; Bi X; Li J; Cheng C; Xue Q; Xing H; Liu Y
    J Headache Pain; 2024 Jul; 25(1):116. PubMed ID: 39030528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model.
    Thaliffdeen R; Yu A; Rascati K
    Clin Drug Investig; 2024 Mar; 44(3):209-217. PubMed ID: 38381352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventive Treatment of Migraine.
    Lipton RB
    Continuum (Minneap Minn); 2024 Apr; 30(2):364-378. PubMed ID: 38568488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gepants.
    Tepper D
    Headache; 2020 May; 60(5):1037-1039. PubMed ID: 32337726
    [No Abstract]   [Full Text] [Related]  

  • 27. A Brief Review of Gepants.
    Li D; Abreu J; Tepper SJ
    Curr Pain Headache Rep; 2023 Sep; 27(9):479-488. PubMed ID: 37531032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update of Gepants in the Treatment of Chronic Migraine.
    Cho S; Kim BK
    Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.
    Lipton RB; Pozo-Rosich P; Blumenfeld AM; Dodick DW; McAllister P; Li Y; Lu K; Dabruzzo B; Miceli R; Severt L; Finnegan M; Trugman JM
    JAMA Netw Open; 2022 Jun; 5(6):e2215499. PubMed ID: 35675076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.
    Strassman AM; Melo-Carrillo A; Houle TT; Adams A; Brin MF; Burstein R
    Cephalalgia; 2022 Aug; 42(9):933-943. PubMed ID: 35332801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
    Schwedt TJ; Lipton RB; Ailani J; Silberstein SD; Tassorelli C; Guo H; Lu K; Dabruzzo B; Miceli R; Severt L; Finnegan M; Trugman JM
    Cephalalgia; 2022 Jan; 42(1):3-11. PubMed ID: 34521260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rimegepant: First Approval.
    Scott LJ
    Drugs; 2020 May; 80(7):741-746. PubMed ID: 32270407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
    Croop R; Goadsby PJ; Stock DA; Conway CM; Forshaw M; Stock EG; Coric V; Lipton RB
    Lancet; 2019 Aug; 394(10200):737-745. PubMed ID: 31311674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
    Blumenfeld AM; Boinpally R; De Abreu Ferreira R; Trugman JM; Dabruzzo B; Ailani J; Lipton RB
    Headache; 2023 Mar; 63(3):322-332. PubMed ID: 36602199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants.
    Ankrom W; Xu J; Vallee MH; Dockendorf MF; Armas D; Boinpally R; Min KC
    J Clin Pharmacol; 2020 Sep; 60(9):1157-1165. PubMed ID: 32297990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gepants for the treatment of migraine.
    Negro A; Martelletti P
    Expert Opin Investig Drugs; 2019 Jun; 28(6):555-567. PubMed ID: 31081399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
    Ailani J; Lipton RB; Hutchinson S; Knievel K; Lu K; Butler M; Yu SY; Finnegan M; Severt L; Trugman JM
    Headache; 2020 Jan; 60(1):141-152. PubMed ID: 31913519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
    Tassorelli C; Onishchenko K; Halker Singh RB; Duan M; Dupont-Benjamin L; Hemstock M; Voller C; McAllister P; Nahas SJ; Gandhi P; Ailani J
    Cephalalgia; 2024 Feb; 44(2):3331024241235156. PubMed ID: 38410850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials.
    Tao X; Yan Z; Meng J; Wang W; Dai Q; Zhou Q; Wang Z; Wang Z
    J Headache Pain; 2022 Jan; 23(1):19. PubMed ID: 35093013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.